CN111346094A - 一种用于治疗支气管炎和支气管哮喘的组合物及其制备方法 - Google Patents
一种用于治疗支气管炎和支气管哮喘的组合物及其制备方法 Download PDFInfo
- Publication number
- CN111346094A CN111346094A CN202010289052.0A CN202010289052A CN111346094A CN 111346094 A CN111346094 A CN 111346094A CN 202010289052 A CN202010289052 A CN 202010289052A CN 111346094 A CN111346094 A CN 111346094A
- Authority
- CN
- China
- Prior art keywords
- bronchial asthma
- bronchitis
- preparation
- treatment
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 22
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims description 11
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960003556 aminophylline Drugs 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 229960002244 promethazine hydrochloride Drugs 0.000 claims abstract description 9
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920002472 Starch Polymers 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 230000002040 relaxant effect Effects 0.000 abstract description 2
- 210000002345 respiratory system Anatomy 0.000 abstract description 2
- 210000002460 smooth muscle Anatomy 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种用于治疗支气管炎和支气管哮喘的复方制剂，由以下组分按照重量制备而成：氨茶碱3～5mg/kg,盐酸异丙嗪为0.1mg/kg，余量为辅料。本发明以氨茶碱和盐酸异丙嗪联合使用，两者相互作用，对呼吸道平滑肌有松弛作用，严格控制两者的使用量，达到治疗支气管炎和支气管哮喘的效果。本发明制备方法简单，便于规模化生产。
Description
技术领域
本发明涉及药物及其制备方法技术领域，特别涉及一种用于治疗支气管炎和支气管哮喘的组合物及其制备方法。
背景技术
支气管哮喘是由多种细胞特别是肥大细胞、嗜酸性粒细胞和T淋巴细胞参与的慢性气道炎症；在易感者中此种炎症可引起反复发作的喘息、气促、胸闷或咳嗽等症状，多在夜间或凌晨发生；此类症状常伴有广泛而多变的呼气流速受限，但可部分地自然缓解或经治疗缓解；此种症状还伴有气道对多种刺激因子反应性增高。
支气管炎是指气管、支气管黏膜及其周围组织的慢性非特异性炎症。支气管炎主要原因为病毒和细菌的反复感染形成了支气管的慢性非特异性炎症。当气温下降、呼吸道小血管痉挛缺血、防御功能下降等利于致病；烟雾粉尘、污染大气等慢性刺激也可发病；吸烟使支气管痉挛、黏膜变异、纤毛运动降低、黏液分泌增多有利感染；过敏因素也有一定关系。
目前治疗支气管哮喘和支气管炎单一药物很难起到好的治疗效果，多种药物联合使用，虽然可以起到很好的效果，但是由于药物的选择和用量选择不好，也很难达到理想的治疗效果。
发明内容
针对现有技术中存在的问题，本发明的目的是提供一种用于治疗支气管炎和支气管哮喘的组合物及其制备方法。
本发明的技术方案如下：
一种用于治疗支气管炎和支气管哮喘的复方制剂，由以下组分按照重量制备而成：
氨茶碱3～5mg/kg,盐酸异丙嗪为0.1mg/kg，余量为辅料。
在上述方案的基础上，所述的用于治疗支气管炎和支气管哮喘的复方制剂，由以下组分按照重量制备而成：
氨茶碱4mg/kg,盐酸异丙嗪为0.1mg/kg，余量为辅料。
所述辅料为淀粉。
一种制备上述的用于治疗支气管炎和支气管哮喘的组合物的方法，具体步骤如下：
按量称取组合物中各组分，分别过80目筛，之后，将各组分混合均匀，分装成0.4g/包。
本发明以氨茶碱和盐酸异丙嗪联合使用，两者相互作用，对呼吸道平滑肌有松弛作用，严格控制两者的使用量，达到治疗支气管炎和支气管哮喘的效果。本发明制备方法简单，便于规模化生产。
具体实施方式
以下实施例用于说明本发明，但不用来限制本发明的范围。在不背离本发明精神和实质的情况下，对本发明方法、步骤或条件所作的修改或替换，均属于本发明的保护范围。
若未特别指明，实施例中所用的技术手段为本领域技术人员所熟知的常规手段。
实施例1
一种用于治疗支气管炎和支气管哮喘的复方制剂，由以下组分按照重量制备而成：
氨茶碱3mg/kg,盐酸异丙嗪为0.1mg/kg，余量为淀粉。
制备方法具体步骤如下：
按量称取组合物中各组分，分别过80目筛，之后，将各组分混合均匀，分装成0.4g/包。
实施例2
一种用于治疗支气管炎和支气管哮喘的复方制剂，由以下组分按照重量制备而成：
氨茶碱4mg/kg,盐酸异丙嗪为0.1mg/kg，余量为淀粉。
制备方法与实施例1相同。
实施例3
一种用于治疗支气管炎和支气管哮喘的复方制剂，由以下组分按照重量制备而成：
氨茶碱5mg/kg,盐酸异丙嗪为0.1mg/kg，余量为淀粉。
制备方法与实施例1相同。
实验例：
诊断标准：
参照《支气管哮喘防治指南》(中华医学会呼吸病学分会支气管哮喘防治指南.中华结核和呼吸杂志，1997，20(5)：261.)中标准，并经X线摄片，血常规等检查诊断为支气管哮喘。临床表现：咳嗽气喘，喉中痰鸣音，痰黄粘稠，痰少不畅，胸中烦闷，夜不能卧。
一般资料：选取符合上述标准的患者共40例，其中男28例，女12例，年龄3--10岁，平均年龄6.4岁，病程5天至一个月。
治疗方法：使用实施例2中制剂，一日三次，每次5g服，三天为一疗程。
疗效评定标准：
痊愈：哮喘完全消失，半年以上未发病；
好转：哮喘明显减轻；
无效：治疗后症状，体征无改善。
疗效结果：
经过三个疗程的治疗，痊愈：22例，好转：18例，无效：0例，总有效率：100％，同时在治疗过程中未发现不良反应。
上述实施方案为本发明最佳的实施方案，但本发明的实施方案并不受上述实施方案的限制，其他的任何不违背本发明原理的条件下，可以通过改变参数的形式所产生的实施例，都包含于本发明的保护范围之内。
Claims (4)
1.一种用于治疗支气管炎和支气管哮喘的复方制剂，其特征在于，由以下组分按照重量制备而成：
氨茶碱3～5mg/kg,盐酸异丙嗪为0.1mg/kg，余量为辅料。
2.根据权利要求1所述的用于治疗支气管炎和支气管哮喘的复方制剂，其特征在于，由以下组分按照重量制备而成：
氨茶碱4mg/kg,盐酸异丙嗪为0.1mg/kg，余量为辅料。
3.根据权利要求1或2所述的用于治疗支气管炎和支气管哮喘的复方制剂，其特征在于所述辅料为淀粉。
4.一种制备权利要求3所述的用于治疗支气管炎和支气管哮喘的组合物的方法，其特征在于，具体步骤如下：
按量称取组合物中各组分，分别过80目筛，之后，将各组分混合均匀，分装成0.4g/包。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010289052.0A CN111346094A (zh) | 2020-04-14 | 2020-04-14 | 一种用于治疗支气管炎和支气管哮喘的组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010289052.0A CN111346094A (zh) | 2020-04-14 | 2020-04-14 | 一种用于治疗支气管炎和支气管哮喘的组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111346094A true CN111346094A (zh) | 2020-06-30 |
Family
ID=71193358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010289052.0A Withdrawn CN111346094A (zh) | 2020-04-14 | 2020-04-14 | 一种用于治疗支气管炎和支气管哮喘的组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111346094A (zh) |
-
2020
- 2020-04-14 CN CN202010289052.0A patent/CN111346094A/zh not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mandelberg et al. | Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis | |
| Alothman et al. | Bronchial constriction and inhaled colistin in cystic fibrosis | |
| Farber et al. | The use of aerosol penicillin and streptomycin in bronchopulmonary infections | |
| CN109999052B (zh) | β-烟酰胺单核苷酸或其前体在制备治疗或缓解呼吸障碍或疾病的药物中的用途 | |
| Agius | Opiate inhalation and occupational asthma | |
| CN113855685A (zh) | 糖皮质激素在制备治疗和/或预防呼吸道病毒感染的药物中的用途 | |
| CN111346094A (zh) | 一种用于治疗支气管炎和支气管哮喘的组合物及其制备方法 | |
| Ruihong et al. | Effect of terbutaline combined with budesonide in treatment of bronchial asthma and rehabilitation nursing. | |
| CN115590858A (zh) | 一种环黄芪醇在制备抗哮喘药物中的应用 | |
| Mattson et al. | A controlled study on the preventive effect of ketotifen, an antiallergic agent, on methacholine‐induced bronchoconstriction in asthmatics | |
| Alyavi et al. | State of Inhalation of Glycerosine on Ventilation-Perfusion Parameters of Patients with Chronic Obstructive Pulmonary Disease | |
| SE534514C2 (sv) | Komposition för behandling av allergiska sjukdomar | |
| CN107261102A (zh) | 一种治疗慢性支气管炎的中药膏 | |
| RU2802133C1 (ru) | Способ предоперационной подготовки больных раком легкого после перенесенной COVID-19 ассоциированной пневмонии | |
| CN114796183A (zh) | 益母草碱在制备用于预防或治疗呼吸系统疾病的药物中的应用 | |
| KR102410183B1 (ko) | 이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도 | |
| Canny | Acute bronchiolitis-recent advances in treatment | |
| WO2024120452A1 (en) | Compositions and methods for prophylaxis and treatment of covid-19 | |
| RU2796736C1 (ru) | Способ предоперационной подготовки больных раком легкого с сопутствующей хронической обструктивной болезнью легких | |
| KR20140015150A (ko) | 급성 악화성 천식의 치료 및 이로부터 고통받는 환자의 입원 가능성의 감소 | |
| Wang et al. | Observation of the Clinical Efficacy of Dingchuan Decoction in the Treatment of Bronchial Asthma | |
| CN102284031B (zh) | 一种治疗支气管疾病及肺气肿的药物组合物 | |
| Ahmad et al. | Concept of Zeequnnafas (Bronchial asthma) in Unani & Conventional Medicine: A Review | |
| RU2308296C9 (ru) | Способ лечения больных с бронхообструктивным синдромом | |
| CN105326790B (zh) | 氨溴索沙丁胺醇溶液剂的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200630 |